


The claimed invention is:

1. A compound of formula (I):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

- 5  $\text{R}^1$  is H;

$\text{R}^2$  is a substituted or unsubstituted  $(\text{C}_1\text{-C}_8)$ alkyl,  $(\text{C}_3\text{-C}_7)$ cycloalkyl,  $(\text{C}_3\text{-C}_9)$ aryl,  $(\text{C}_3\text{-C}_9)$ heteroaryl, amide, amino,  $(\text{C}_1\text{-C}_8)$ alcohol,  $(\text{C}_3\text{-C}_9)$ heterocycloalkyl,  $(\text{C}_1\text{-C}_8)$ alkyl $(\text{C}_3\text{-C}_9)$ aryl,  $(\text{C}_1\text{-C}_8)$ alkylamine,  $(\text{C}_1\text{-C}_8)$ alkylamide; or  $\text{R}^1$  and  $\text{R}^2$  taken together with the nitrogen to which they are attached form a substituted or

- 10 unsubstituted heterocycloalkyl or heteroaryl;

$\text{R}^3$  is independently selected from the group consisting of H,  $(\text{C}_1\text{-C}_8)$ alkyl, halo,  $(\text{C}_1\text{-C}_8)$ alkoxy, sulfonyl, cyano, and keto;

$n$  is an integer from 0-5;

- 15 with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.


2. A compound of claim 1, wherein  $\text{R}^3$  is H, bromo, chloro, cyano, methoxy,  $(\text{C}_1\text{-C}_8)$ alkyl- $\text{SO}_2$ -, or  $(\text{C}_1\text{-C}_8)$ alkyl $\text{C}(=\text{O})$ -.

20

3. A compound of claim 1, wherein  $n$  is 0-4.

4. A compound of claim 3, wherein  $n$  is 0-1.

5. A compound of formula (II):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof  
where:

- 5         $R^1$  is H;


$R^2$  is a substituted or unsubstituted ( $C_1$ - $C_8$ )alcohol, ( $C_3$ - $C_9$ )cycloalkyl, ( $C_3$ - $C_9$ )heterocycloalkyl, ( $C_3$ - $C_9$ )heteroaryl, ( $C_1$ - $C_8$ )alkylamine, ( $C_1$ - $C_8$ )alkyl( $C_3$ - $C_9$ )aryl, or ( $C_1$ - $C_8$ )alkylamide; or  $R^1$  and  $R^2$  taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl group;

- 10        Het is a substituted or unsubstituted heterocyclyl or heteroaryl group  
containing at least one heteroatom selected from N, O and S.

6. A compound of claim 5, wherein Het is a substituted or unsubstituted  
( $C_5$ - $C_{10}$ )heterocyclyl or heteroaryl group containing at least one heteroatom selected  
15 from N, O and S.

7. A compound of claim 6, wherein Het is a substituted or unsubstituted furanyl,  
thienyl, pyridyl, or benzofuranyl group.

- 20 8. A compound of formula (III):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

$R^1$  is H;

- 25         $R^2$  is a substituted or unsubstituted ( $C_1$ - $C_8$ )alcohol;

Ar is a substituted or unsubstituted (C<sub>3</sub>-C<sub>9</sub>)aryl group;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

5

9. A compound of claim 8, wherein R<sup>2</sup> is a substituted or unsubstituted (C<sub>1</sub>-C<sub>5</sub>)alcohol.

10. A compound of claim 9, wherein R<sup>2</sup> is a substituted or unsubstituted (C<sub>3</sub>-C<sub>5</sub>)alcohol.

10

11. A compound of claim 8, wherein Ar is a substituted or unsubstituted naphthyl group.

15 12. A pharmaceutical composition comprising a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier.

13. A method of preventing or treating a TGF-related disease state in a mammal (animal or human) comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1-11 to the animal or human suffering from the TGF-related disease state.

20

14. A method of claim 13, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

25